Health Canada has authorized the booster dose of Moderna, Inc.’s (MRNA) COVID-19 vaccine, Spikevax. The dose provided by the American pharmaceutical and biotechnology company can be administered at the 50 µg level to people aged 18 and above. Notably, the dose should be administered minimum after six months following the primary vaccinations.  Health Canada’s authorization was based on the scientific evidence provided by the company, which included a data analysis from the Phase 2 clinical study of mRNA-1273. Notably, the analysis was amended to offer a booster dose of mRNA-1273 at the 50 µg dose level to interested participants 6-8 months following their second dose, the company said.
https://www.tipranks.com/news/modernas-spikevax-booster-approved-by-health-canada?utm_source=advfn.com&utm_medium=referral
Moderna (NASDAQ:MRNA)
Historical Stock Chart
From Dec 2021 to Jan 2022 Click Here for more Moderna Charts.
Moderna (NASDAQ:MRNA)
Historical Stock Chart
From Jan 2021 to Jan 2022 Click Here for more Moderna Charts.